Join

Compare · NVO vs SPRC

NVO vs SPRC

Side-by-side comparison of Novo Nordisk A/S (NVO) and SciSparc Ltd. (SPRC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and SPRC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $195.92B, about 39974.5x SPRC ($4.9M).
  • Over the past year, NVO is down 45.1% and SPRC is down 85.7% - NVO leads by 40.6 points.
  • NVO has been more active in the news (8 items in the past 4 weeks vs 5 for SPRC).
  • NVO has more recent analyst coverage (25 ratings vs 0 for SPRC).
PerformanceNVO-45.07%SPRC-85.66%
2025-06-13+0.00%2026-06-12
MetricNVOSPRC
Company
Novo Nordisk A/S
SciSparc Ltd.
Price
$43.88-0.20%
$8.68-9.82%
Market cap
$195.92B
$4.9M
1M return
-6.80%
+41.98%
1Y return
-45.07%
-85.66%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
News (4w)
8
5
Recent ratings
25
0
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

SPRC

SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.

Latest NVO

Latest SPRC